Abstract
This article introduces one of the most diverse classes of direct-acting antivirals for hepatitis C, the nucleoside and non-nucleoside NS5B polymerase inhibitors. Through a systematic review of the published literature, we describe their structure, mechanism of action, issues with resistance, and clinical effectiveness shown in the latest clinical trials. Direct-acting antiviral combination trials that have already shown some early promising results even in the setting of interferon-sparing antiviral regimens are discussed.
Original language | English (US) |
---|---|
Pages (from-to) | 611-626 |
Number of pages | 16 |
Journal | Clinics in Liver Disease |
Volume | 15 |
Issue number | 3 |
DOIs | |
State | Published - Aug 1 2011 |
Externally published | Yes |
Keywords
- Hepatitis C virus
- Non-nucleoside inhibitors
- NS5B nucleoside inhibitors
- Polymerase inhibitors
ASJC Scopus subject areas
- Hepatology